Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy
ESC Heart Failure · 01.12.2024 · 11 (6) · 4314-4324
DOI: 10.1002/ehf2.14971 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 29.08.2024. Verfasst von Pablo Garcia-Pavia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Aims
Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics. We examined the prevalence and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy of unascertained aetiology. Methods and results TTRACK was a multicentre, non-interventional, cross-sectional epidemiologic study funded by Pfizer and conducted in 20 hospitals and medical centres in 11 countries (NCT03842163). Eligible patients were aged ≥50 years, had hypertrophic cardiomyopathy (maximal end-diastolic left ventricular wall thickness ≥15 mm on echocardiogram) without an identified genetic or alternative origin at study enrolment, and underwent 99mTechnetium bone scintigraphy, with or without single photon emission computed tomography (SPECT). Cardiac-versus-bone uptake on scans was visually scored from 0 to 3 (Perugini scoring). Patients with grades 1–3 underwent monoclonal protein and laboratory testing and transthyretin (TTR) gene sequencing. Of 766 eligible patients, 691 (90.2%) had scintigraphy alone and 75 (9.8%) scintigraphy plus SPECT. Two hundred and eight patients (27.2%) had grade 2 or 3 cardiac uptake on scintigraphy; 144 (18.8%) had grade 2 or 3 cardiac uptake and no evidence of plasma cell dyscrasia and were diagnosed with transthyretin amyloid cardiomyopathy. Of patients with transthyretin amyloid cardiomyopathy, 11 (7.6%) had a pathogenic TTR gene variant and 34 (23.8%), 74 (51.7%), and 35 (24.5%) had New York Heart Association class I, II, and III/IV heart failure (HF) symptoms, respectively. Clinical and laboratory diagnostic characteristics were observed in ≥90% of patients with transthyretin amyloid cardiomyopathy. The characteristics most strongly associated with transthyretin amyloid cardiomyopathy on multivariable analysis were carpal tunnel syndrome (odds ratio [OR] 54.3; P < 0.0001) and male sex (OR 7.9; P < 0.0001).
Conclusions
In the TTRACK study, almost one in five patients ≥50 years of age with hypertrophic cardiomyopathy had transthyretin amyloid cardiomyopathy. Greater awareness of the frequency and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy are needed to help improve early detection of this debilitating but treatable disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain.
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
- Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcon, Madrid, Spain.
- Department of Cardiology and French National Reference Centre for Cardiac Amyloidosis, Hôpitaux Universitaires Henri-Mondor AP-HP, and IMRB, INSERM, Université Paris Est Créteil, Créteil, France.
- L'institut Du Thorax and Nuclear Medicine Department, Nantes Université, CHU Nantes, Nantes, France.
- Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV-ISCIII, A Coruña, Spain.
ORCID-Profile: Pablo Garcia-Pavia
Förderung
- Pfizer
Zitieren
APA
Garcia-Pavia, P., Damy, T., Piriou, N., Barriales-Villa, R., Cappelli, F., Bahus, C., Munteanu, C., Keohane, D., Mallaina, P., Elliott, P., & TTRACK investigators (2024). Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy. ESC Heart Failure, 11(6), 4314-4324. https://doi.org/10.1002/ehf2.14971
Vancouver
Garcia-Pavia P, Damy T, Piriou N, Barriales-Villa R, Cappelli F, Bahus C, et al. Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy. ESC Heart Failure. 2024;11(6):4314-4324. doi:10.1002/ehf2.14971
BibTeX
@article{GarciaPavia2024,
author = {Garcia-Pavia, Pablo and Damy, Thibaud and Piriou, Nicolas and Barriales-Villa, Roberto and Cappelli, Francesco and Bahus, Catherine and Munteanu, Carmen and Keohane, Denis and Mallaina, Pablo and Elliott, Perry and TTRACK investigators, TTRACK investigators},
title = {Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2024},
volume = {11},
number = {6},
pages = {4314--4324},
doi = {10.1002/ehf2.14971}
}
EUVIMED